BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 31175057)

  • 1. Novel oncogene 5MP1 reprograms c-Myc translation initiation to drive malignant phenotypes in colorectal cancer.
    Sato K; Masuda T; Hu Q; Tobo T; Gillaspie S; Niida A; Thornton M; Kuroda Y; Eguchi H; Nakagawa T; Asano K; Mimori K
    EBioMedicine; 2019 Jun; 44():387-402. PubMed ID: 31175057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linc00659, a long noncoding RNA, acts as novel oncogene in regulating cancer cell growth in colorectal cancer.
    Tsai KW; Lo YH; Liu H; Yeh CY; Chen YZ; Hsu CW; Chen WS; Wang JH
    Mol Cancer; 2018 Mar; 17(1):72. PubMed ID: 29523145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC.
    Takahashi Y; Sheridan P; Niida A; Sawada G; Uchi R; Mizuno H; Kurashige J; Sugimachi K; Sasaki S; Shimada Y; Hase K; Kusunoki M; Kudo S; Watanabe M; Yamada K; Sugihara K; Yamamoto H; Suzuki A; Doki Y; Miyano S; Mori M; Mimori K
    Ann Oncol; 2015 May; 26(5):935-942. PubMed ID: 25632068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GTF2IRD1 on chromosome 7 is a novel oncogene regulating the tumor-suppressor gene TGFβR2 in colorectal cancer.
    Nambara S; Masuda T; Kobayashi Y; Sato K; Tobo T; Koike K; Noda M; Ogawa Y; Kuroda Y; Ito S; Eguchi H; Sugimachi K; Mimori K
    Cancer Sci; 2020 Feb; 111(2):343-355. PubMed ID: 31758608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
    Yang L; Lei Q; Li L; Yang J; Dong Z; Cui H
    Clin Epigenetics; 2019 Dec; 11(1):199. PubMed ID: 31888761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinase GSK3β functions as a suppressor in colorectal carcinoma through the FTO-mediated MZF1/c-Myc axis.
    Zhang Z; Gao Q; Wang S
    J Cell Mol Med; 2021 Mar; 25(5):2655-2665. PubMed ID: 33533172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global analysis of RNA-binding proteins identifies a positive feedback loop between LARP1 and MYC that promotes tumorigenesis.
    Desi N; Tong QY; Teh V; Chan JJ; Zhang B; Tabatabaeian H; Tan HQ; Kapeli K; Jin W; Lim CY; Kwok ZH; Tan HT; Wang S; Siew BE; Lee KC; Chong CS; Tan KK; Yang H; Kappei D; Yeo GW; Chung MCM; Tay Y
    Cell Mol Life Sci; 2022 Feb; 79(3):147. PubMed ID: 35195778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of MYC-regulated long noncoding RNAs in cell cycle regulation and tumorigenesis.
    Kim T; Jeon YJ; Cui R; Lee JH; Peng Y; Kim SH; Tili E; Alder H; Croce CM
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25663692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroartemisinin is potential therapeutics for treating late-stage CRC by targeting the elevated c-Myc level.
    Hu X; Fatima S; Chen M; Huang T; Chen YW; Gong R; Wong HLX; Yu R; Song L; Kwan HY; Bian Z
    Cell Death Dis; 2021 Nov; 12(11):1053. PubMed ID: 34741022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
    Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
    Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-181d and c-myc-mediated inhibition of CRY2 and FBXL3 reprograms metabolism in colorectal cancer.
    Guo X; Zhu Y; Hong X; Zhang M; Qiu X; Wang Z; Qi Z; Hong X
    Cell Death Dis; 2017 Jul; 8(7):e2958. PubMed ID: 28749470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic splicing abnormalities induced by DEAD-Box Helicase 56 amplification in colorectal cancer.
    Kouyama Y; Masuda T; Fujii A; Ogawa Y; Sato K; Tobo T; Wakiyama H; Yoshikawa Y; Noda M; Tsuruda Y; Kuroda Y; Eguchi H; Ishida F; Kudo SE; Mimori K
    Cancer Sci; 2019 Oct; 110(10):3132-3144. PubMed ID: 31390121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Omics Analysis of a Novel Small-Molecule Inhibitor of Chemoresistant Oncogenic Signatures in Colorectal Cancer Cell with Antitumor Effects.
    Huang TH; Mokgautsi N; Huang YJ; Wu ATH; Huang HS
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SNX16 activates c-Myc signaling by inhibiting ubiquitin-mediated proteasomal degradation of eEF1A2 in colorectal cancer development.
    Shen Z; Li Y; Fang Y; Lin M; Feng X; Li Z; Zhan Y; Liu Y; Mou T; Lan X; Wang Y; Li G; Wang J; Deng H
    Mol Oncol; 2020 Feb; 14(2):387-406. PubMed ID: 31876369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockage of Glyoxalase I Inhibits Colorectal Tumorigenesis and Tumor Growth via Upregulation of STAT1, p53, and Bax and Downregulation of c-Myc and Bcl-2.
    Chen Y; Fang L; Zhang J; Li G; Ma M; Li C; Lyu J; Meng QH
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28282916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation.
    Wang X; Wu F; Wang H; Duan X; Huang R; Tuersuntuoheti A; Su L; Yan S; Zhao Y; Lu Y; Li K; Yao J; Luo Z; Guo L; Liu J; Chen X; Lu Y; Hu H; Li X; Bao M; Bi X; Du B; Miao S; Cai J; Wang L; Zhou H; Ying J; Song W; Zhao H
    J Exp Clin Cancer Res; 2020 Aug; 39(1):147. PubMed ID: 32746883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of the c-Myc/miR-200b-3p/PRDX2 regulatory loop enhances tumor metastasis and chemotherapeutic resistance in colorectal cancer.
    Lv Z; Wei J; You W; Wang R; Shang J; Xiong Y; Yang H; Yang X; Fu Z
    J Transl Med; 2017 Dec; 15(1):257. PubMed ID: 29258530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional analysis of the AUG- and CUG-initiated forms of the c-Myc protein.
    Blackwood EM; Lugo TG; Kretzner L; King MW; Street AJ; Witte ON; Eisenman RN
    Mol Biol Cell; 1994 May; 5(5):597-609. PubMed ID: 7919540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis.
    Taha-Mehlitz S; Bianco G; Coto-Llerena M; Kancherla V; Bantug GR; Gallon J; Ercan C; Panebianco F; Eppenberger-Castori S; von Strauss M; Staubli S; Bolli M; Peterli R; Matter MS; Terracciano LM; von Flüe M; Ng CKY; Soysal SD; Kollmar O; Piscuoglio S
    Theranostics; 2021; 11(9):4011-4029. PubMed ID: 33754045
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel evidence for a PIWI-interacting RNA (piRNA) as an oncogenic mediator of disease progression, and a potential prognostic biomarker in colorectal cancer.
    Weng W; Liu N; Toiyama Y; Kusunoki M; Nagasaka T; Fujiwara T; Wei Q; Qin H; Lin H; Ma Y; Goel A
    Mol Cancer; 2018 Jan; 17(1):16. PubMed ID: 29382334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.